Skip to main content

Table 3 Secondary clinical outcomes

From: Effect of erythromycin on mortality and the host response in critically ill patients with sepsis: a target trial emulation

 

Unadjusted

PS matched

PS weighted

Erythromycin (n = 235)

Controls (n = 470)

P value

Erythromycin (n = 211)

Controls (n = 211)

P value

Erythromycin

Controls

P value

30-day mortality

60 (25.9)

117 (25.4)

0.93

54 (26.0)

56 (27.3)

0.91

27.7

25.9

0.67

 ICU length of stay, days

8 [5, 14]

7 [4, 11]

< 0.001

8 [5, 13]

8 [5, 13]

0.51

7 [5, 13]

7 [4, 11]

0.06

 Hospital length of stay, days

23 [13, 40]

19 [11, 36]

0.031

22 [12, 37.5]

21 [12, 39]

0.61

21 [10, 37]

20 [11, 37]

0.69

 Duration of mechanical ventilation, days*

6 [4, 11]

5 [3, 9]

0.001

6 [4, 11]

6 [3, 10]

0.48

6 [4, 10]

5 [3, 9]

0.11

 ΔSOFA day 4†

−1.5 (2.9)

−1.2 (2.6)

0.35

−1.5 (2.9)

−1.6 (2.7)

0.79

−1.3 (2.8)

−1.4 (2.7)

0.75

 Incidence of ICU-acquired infections

42 (17.9)

51 (10.9)

0.013

35 (16.6)

32 (15.2)

0.79

13.8

12.0

0.51

 Incidence of ICU-acquired AKI

17 (7.2)

24 (5.1)

0.31

16 (7.6)

15 (7.1)

> 0.99

6.4

5.5

0.66

 Incidence of ICU-acquired ARDS

9 (3.8)

19 (4.0)

> 0.99

8 (3.8)

13 (6.2)

0.38

3.3

4.6

0.43

  1. AKI acute kidney injury, ARDS acute respiratory distress syndrome, ICU intensive care unit, PS propensity score, ΔSOFA change in modified sequential organ failure assessment score (excluding the neurological component) from admission to day 2, 3 or 4
  2. Categorical data are displayed as count (percentage) or and compared using Fisher's exact test (unadjusted) or McNemar's test (after PS matching), or displayed as percentage and compared using a Chi-square test‡ (after PS weighting)
  3. Normally distributed continuous data are displayed as mean (standard deviation) and compared using a t-test (unadjusted), a paired t-test (after PS matching) or a t-test‡ (after PS weighting)
  4. Non-normally distributed continuous data are displayed as median [interquartile range] and compared using Wilcoxon's rank-sum test (unadjusted), Wilcoxon's signed-rank test or Wilcoxon rank-sum test‡ (after PS weighting)
  5. *In those who were mechanically ventilated at ICU admission: 225/235 (96.6%) in the erythromycin group, 419/470 (89.3%) in the control group (in the unadjusted population)
  6. †Missing in 21/235 (8.9%) in the erythromycin group and 102/470 (21.7%) in the control group, see Additional file 1: Methods and Additional file 1: Table 3 for details
  7. ‡For weighted samples, as provided in the survey R package